Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.46 |
| ▸ | SSTR2 | P30874 | 3/20 | 0.46 |
| ▸ | BRD4 | O60885 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1284132 | 0.93 | MAPT (0.49) | MAPTTP53KCNH2SSTR2BRD4 | |
| SCHEMBL1284144 | 0.93 | MAPT (0.49) | MAPTTP53KCNH2SSTR2BRD4 | |
| SCHEMBL1284530 | 0.92 | MAPT (0.50) | MAPTTP53KCNH2SSTR2ALDH1A1 | |
| SCHEMBL1625503 | 0.87 | LMNA (0.58) | MAPTTP53KCNH2SSTR2ALDH1A1 | |
| SCHEMBL1284508 | 0.85 | MAPT (0.46) | MAPTTP53KCNH2ALDH1A1LMNA | |
| SCHEMBL1283898 | 0.85 | KCNH2 (0.51) | MAPTTP53KCNH2SSTR2BRD4 | |
| SCHEMBL1284637 | 0.85 | MAPT (0.49) | MAPTTP53KCNH2SSTR2BRD4 | |
| SCHEMBL1625200 | 0.84 | DGAT2 (0.47) | MAPTTP53KCNH2SSTR2ALDH1A1 | |
| SCHEMBL1283909 | 0.84 | MAPT (0.48) | MAPTTP53KCNH2BRD4ALDH1A1 | |
| SCHEMBL1623592 | 0.83 | LMNA (0.52) | MAPTTP53KCNH2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088752-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2012-04-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088752-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SHH, GLI1, SMO | MAPT 3104/4885TP53 537/4885KCNH2 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.